These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 9109749)

  • 1. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease.
    Bodick NC; Offen WW; Levey AI; Cutler NR; Gauthier SG; Satlin A; Shannon HE; Tollefson GD; Rasmussen K; Bymaster FP; Hurley DJ; Potter WZ; Paul SM
    Arch Neurol; 1997 Apr; 54(4):465-73. PubMed ID: 9109749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease.
    Bodick NC; Offen WW; Shannon HE; Satterwhite J; Lucas R; van Lier R; Paul SM
    Alzheimer Dis Assoc Disord; 1997; 11 Suppl 4():S16-22. PubMed ID: 9339268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of xanomeline in Alzheimer disease: cognitive improvement measured using the Computerized Neuropsychological Test Battery (CNTB).
    Veroff AE; Bodick NC; Offen WW; Sramek JJ; Cutler NR
    Alzheimer Dis Assoc Disord; 1998 Dec; 12(4):304-12. PubMed ID: 9876958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease.
    Morris JC; Cyrus PA; Orazem J; Mas J; Bieber F; Ruzicka BB; Gulanski B
    Neurology; 1998 May; 50(5):1222-30. PubMed ID: 9595967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.
    Gault LM; Lenz RA; Ritchie CW; Meier A; Othman AA; Tang Q; Berry S; Pritchett Y; Robieson WZ
    Alzheimers Res Ther; 2016 Oct; 8(1):44. PubMed ID: 27756421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial.
    De Jesus Moreno Moreno M
    Clin Ther; 2003 Jan; 25(1):178-93. PubMed ID: 12637119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists.
    Mirza NR; Peters D; Sparks RG
    CNS Drug Rev; 2003; 9(2):159-86. PubMed ID: 12847557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of a loading-dose regimen versus a no-loading-dose regimen of metrifonate in the symptomatic treatment of Alzheimer's disease: a randomized, double-masked, placebo-controlled trial. Metrifonate Study Group.
    Jann MW; Cyrus PA; Eisner LS; Margolin DI; Griffin T; Gulanski B
    Clin Ther; 1999 Jan; 21(1):88-102. PubMed ID: 10090427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. Metrifonate Study Group.
    Raskind MA; Cyrus PA; Ruzicka BB; Gulanski BI
    J Clin Psychiatry; 1999 May; 60(5):318-25. PubMed ID: 10362441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of central muscarinic-1 receptor stimulation on blood pressure regulation.
    Medina A; Bodick N; Goldberger AL; Mac Mahon M; Lipsitz LA
    Hypertension; 1997 Mar; 29(3):828-34. PubMed ID: 9052903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia.
    Brannan SK; Sawchak S; Miller AC; Lieberman JA; Paul SM; Breier A
    N Engl J Med; 2021 Feb; 384(8):717-726. PubMed ID: 33626254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia.
    Shekhar A; Potter WZ; Lightfoot J; Lienemann J; Dubé S; Mallinckrodt C; Bymaster FP; McKinzie DL; Felder CC
    Am J Psychiatry; 2008 Aug; 165(8):1033-9. PubMed ID: 18593778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of a novel acetylcholinesterase inhibitor octohydroaminoacridine in mild-to-moderate Alzheimer's disease: a Phase II multicenter randomised controlled trial.
    Xiao S; Wang T; Ma X; Qin Y; Li X; Zhao Z; Liu X; Wang X; Xie H; Jiang Q; Sun L; Luo B; Shang L; Chen W; Bai Y; Tang M; He M; Wu L; Ma Q; Hou D; He J
    Age Ageing; 2017 Sep; 46(5):767-773. PubMed ID: 28419192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of eptastigmine for the treatment of patients with Alzheimer's disease.
    Imbimbo BP; Martelli P; Troetel WM; Lucchelli F; Lucca U; Thal LJ
    Neurology; 1999 Mar; 52(4):700-8. PubMed ID: 10078713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial.
    Rockwood K; Mintzer J; Truyen L; Wessel T; Wilkinson D
    J Neurol Neurosurg Psychiatry; 2001 Nov; 71(5):589-95. PubMed ID: 11606667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclandelate in the treatment of patients with mild to moderate primary degenerative dementia of the Alzheimer type or vascular dementia: experience from a placebo controlled multi-center study.
    Weyer G; Eul A; Milde K; Wierich W; Herrmann WM
    Pharmacopsychiatry; 2000 May; 33(3):89-97. PubMed ID: 10855459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lu 25-109, a muscarinic agonist, fails to improve cognition in Alzheimer's disease. Lu25-109 Study Group.
    Thal LJ; Forrest M; Loft H; Mengel H
    Neurology; 2000 Jan; 54(2):421-6. PubMed ID: 10668706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended-release physostigmine in Alzheimer disease: a multicenter, double-blind, 12-week study with dose enrichment. Physostigmine Study Group.
    van Dyck CH; Newhouse P; Falk WE; Mattes JA
    Arch Gen Psychiatry; 2000 Feb; 57(2):157-64. PubMed ID: 10665618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The M₁/M₄ preferring agonist xanomeline reverses amphetamine-, MK801- and scopolamine-induced abnormalities of latent inhibition: putative efficacy against positive, negative and cognitive symptoms in schizophrenia.
    Barak S; Weiner I
    Int J Neuropsychopharmacol; 2011 Oct; 14(9):1233-46. PubMed ID: 21211109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Donepezil for vascular cognitive impairment.
    Malouf R; Birks J
    Cochrane Database Syst Rev; 2004; (1):CD004395. PubMed ID: 14974068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.